STOCK TITAN

Artivion, Inc. Stock Price, News & Analysis

AORT NYSE

Welcome to our dedicated page for Artivion news (Ticker: AORT), a resource for investors and traders seeking the latest updates and insights on Artivion stock.

Artivion, Inc. (AORT) pioneers life-saving medical devices for aortic disease treatment, serving cardiac and vascular specialists worldwide. This dedicated news hub provides investors and medical professionals with timely updates on company developments, clinical advancements, and strategic initiatives.

Access official press releases, earnings reports, and regulatory updates in one centralized location. Track innovations across Artivion's core product lines including aortic stent grafts, surgical sealants, and implantable tissues. Our curated news collection helps stakeholders monitor clinical trial progress, partnership announcements, and market expansion efforts.

Key updates include FDA clearances, international regulatory milestones, and peer-reviewed study results from ongoing trials. Discover how Artivion's technologies continue to reshape treatment protocols in complex cardiovascular surgeries through verified clinical outcomes and surgeon testimonials.

Bookmark this page for continuous access to verified information about AORT's medical advancements. Check regularly for new developments impacting the future of aortic disease management and surgical innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.71%
Tags
none
-
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.72%
Tags
conferences acquisition
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.61%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.98%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.66%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.39%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.78%
Tags
Rhea-AI Summary

Artivion, Inc. (NYSE: AORT), a leader in cardiac and vascular surgery solutions, announced that it will release its first quarter 2023 financial results on May 4, 2023, post-market. A teleconference call and live webcast will follow at 4:30 p.m. ET, hosted by Chairman and CEO Pat Mackin. Investors can access the teleconference by dialing 862-298-0702. The replay will be available within an hour post-event. This announcement emphasizes Artivion's ongoing commitment to transparency with its stakeholders regarding its financial performance. The company's innovative product lines, including aortic stent grafts and surgical sealants, aim to address complex cardiac challenges, positioning Artivion within the competitive landscape of over 100 countries globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.62%
Tags

FAQ

What is the current stock price of Artivion (AORT)?

The current stock price of Artivion (AORT) is $28.53 as of May 8, 2025.

What is the market cap of Artivion (AORT)?

The market cap of Artivion (AORT) is approximately 1.2B.
Artivion, Inc.

NYSE:AORT

AORT Rankings

AORT Stock Data

1.20B
37.65M
5.91%
92.24%
9.1%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
KENNESAW